Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease.
Maintaining normal levels of lipid indicators can significantly reduce the risk of
atherosclerotic cardiovascular disease and mortality. Empirical evidence suggests that
adherence to Pueraria lobata and Pueraria thomsonii is useful for improving dyslipidemia, but
evidence from randomized controlled trials is lacking. This randomized, double-blind
controlled trial is therefore designed to evaluate the efficacy and safety of Pueraria lobata
and Pueraria thomsonii for dyslipidemia.
Phase:
N/A
Details
Lead Sponsor:
Jiangxi University of Traditional Chinese Medicine